Metastatic lung-cell cancer treatment with Erlotinib: its cutaneous side effects and practical management advice
Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y, Yamazaki N, Kishi A.
J Am Acad Dermatol. 2013 Sep;69(3):463-72. doi: 10.1016/j.jaad.2013.02.025.
- Targeted treatments against cancers have enhanced therapeutic properties as compared with older treatments. But with this also comes an array of new unwanted side-effects which are the results of these specific targets.
- Erlotinib (metastatic non-small cell lung cancer) is no exception and with the side-effects also comes a mangement plan:
- Acneiform rash
- Xeroderma
- Pruritus
- Paronychia
- The authors also cover other side-effects, preventive measures as well as indications when erlotinib should be stopped.
For full access to the free article in the Journal of American Academy of Dermatology (JAAD), click here.
JAAD: click here to view abstracts from the current edition, articles in press, most cited articles and top 25 articles.
Contributors
Dr Christophe Hsu – dermatologist. Geneva, Switzerland
